ClinicalTrials.gg
CompletedNCT02531815Updated Aug 12, 2016

Dose Escalation Study of PF-06741086 In Healthy Subjects

A Phase 1 interventional study of PF-06741086 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-12.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.

02

Conditions studied

  • Healthy

Keywords

  • safety
  • tolerability
  • pharmacokinetics
  • pharmacodynamics
  • Phase 1
  • first in human
  • monoclonal antibody
  • tissue factor pathway inhibitor
  • japanese
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs) and 100 kg (220 lbs).

Exclusion criteria

Exclusion Criteria:

  • Increased risk of thrombosis (coronary artery disease, hypercholesterolemia, diabetes)
  • Use of nicotine/tobacco products
  • Clotting disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 2 (SC) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 3 (SC) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 4 (Intravenous [IV]) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 5 (IV) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 6 (IV) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 7 (IV) PF-06741086, Placebo

    Biological: PF-06741086 · Drug: Placebo

  • Experimental
    Cohort 8 (subcutaneous [SC]) PF-06741086

    Biological: PF-06741086

Interventions

  • BiologicalPF-06741086

    PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

  • DrugPlacebo

    Placebo for PF-06741086, single dose

    Also known as: saline placebo

06

What researchers measure

Primary outcomes

  1. Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs

    Time frame: Day 1 up to Day 84

  2. Percentage of subjects with laboratory abnormalities

    Time frame: Day 1 up to Day 84

  3. Number of subjects with change from baseline in vital signs

    blood pressure, pulse rate, temperature, respiration rate

    Time frame: Day 1 up to Day 84

  4. Number of subjects with change from baseline in electrocardiogram (ECG) parameters

    Time frame: Day 1 to Day 84

  5. Percentage of subjects with changes from baseline in physical examination

    Time frame: Day 1 to Day 84

  6. Percentage of subjects with infusion site reactions

    Time frame: Day 1 up to Day 7

  7. Percentage of subjects with injection site reactions

    Time frame: Day 1 to Day 7

Secondary outcomes

  1. Plasma PF-06741086 concentrations

    Time frame: Day 1 up to Day 84

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Day 1 up to Day 84

  3. Time for Cmax (Tmax)

    Time frame: Day 1 up to Day 84

  4. Area under the curve from time zero to last quantifiable concentration (AUClast)

    Time frame: Day 1 up to Day 84

  5. Terminal half-life (t 1/2)

    Time frame: Day 1 up to Day 84

  6. Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)

    Time frame: Day 1 up to Day 84

  7. Volume of distribution at steady state (Vss)

    Intravenous administration only

    Time frame: Day 1 up to Day 84

  8. Apparent volume of distribution (Vz/F)

    Subcutaneous administration only

    Time frame: Day 1 up to Day 84

  9. Clearance (CL)

    Intravenous administration only

    Time frame: Day 1 up to Day 84

  10. Apparent clearance (CL/F)

    Subcutaneous administration only

    Time frame: Day 1 up to Day 84

  11. Bioavailability (F) [F = AUC (inf,sc) / AUC (inf,iv)]

    Time frame: Day 1 up to Day 84

  12. Mean residence time (MRT)

    Time frame: Day 1 up to Day 84

  13. Total tissue factor pathway inhibitor concentrations over time

    Time frame: Day 1 up to Day 84

  14. Thrombin generation

    may include lag time, peak thrombin generation, and endogenous thrombin generation potential

    Time frame: Day 1 up to Day 84

  15. Prothrombin fragment 1+2 (PF1+2) concentrations over time

    Time frame: Day 1 up to Day 84

  16. D-dimer concentrations over time

    Time frame: Day 1 up to Day 84

  17. Dilute prothrombin time (dPT)

    Time frame: Day 1 up to Day 84

  18. Frequency of anti-drug antibody (ADA) and neutralizing antibody (NAb) production

    Immunogenicity

    Time frame: Day 1 up to Day 84

07

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Aug 25, 2015
Start
Aug 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Last update
Aug 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02531815
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 25, 2015
Start date
Aug 2015
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Aug 12, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Marstacimab

Start the discussion